Search Results for: INTS4

14 interactions involving INTS4 - integrator complex subunit 4 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ACOT2 acyl-CoA thioesterase 2
  • Mitochondrial Fatty Acid Beta-Oxidation
  • Peroxisomal protein import
  • Peroxisomal protein import
  • Mitochondrial protein degradation
Novel ENOX2 ecto-NOX disulfide-thiol exchanger 2
  • Idronoxil
Novel FAM181B family with sequence similarity 181 member B
Novel FOLR1 folate receptor alpha
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
  • COPI-mediated anterograde transport
  • Folic acid
  • Vintafolide
  • Farletuzumab
  • Mirvetuximab soravtansine
  • Pafolacianine
Novel NARS2 asparaginyl-tRNA synthetase 2, mitochondrial
  • Mitochondrial tRNA aminoacylation
  • Asparagine
HGS hepatocyte growth factor-regulated tyrosine kinase substrate
  • EGFR downregulation
  • Lysosome Vesicle Biogenesis
  • Ub-specific processing proteases
  • Negative regulation of MET activity
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • RHOU GTPase cycle
  • Endosomal Sorting Complex Required For Transport (ESCRT)
  • Inhibition of membrane repair
  • Prevention of phagosomal-lysosomal fusion
  • RHOBTB3 ATPase cycle
  • Citric acid
KIAA0513 KIAA0513
LHX3 LIM homeobox 3
  • Regulation of expression of SLITs and ROBOs
  • Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
MEIS3 Meis homeobox 3
PCM1 pericentriolar material 1
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
PYGM glycogen phosphorylase, muscle associated
  • Glycogen breakdown (glycogenolysis)
  • Glycogen breakdown (glycogenolysis)
  • Pyridoxal phosphate
  • Beta-D-Glucopyranose Spirohydantoin
  • (5S,7R,8S,9S,10R)-3-Amino-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione
  • alpha-D-glucose 6-phosphate
  • N-beta-D-glucopyranosylacetamide
  • Monofluorophosphate ion
  • Beta-D-Glucose
  • 3,8,9,10-tetrahydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione
  • Nojirimycine Tetrazole
  • Indirubin-5-sulphonate
  • 2-Deoxy-Glucose-6-Phosphate
  • C-(1-hydrogyl-beta-D-glucopyranosyl) formamide
  • alpha-D-glucopyranosyl-2-carboxylic acid amide
  • alpha-D-glucose-1-phosphate
  • 8,9,10-Trihydroxy-7-hydroxymethyl-2-thioxo-6-oxa-1,3-diaza-spiro[4.5]decan-4-one
  • 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid
  • 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole
  • N-acetyl-N'-beta-D-glucopyranosyl urea
  • 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole
  • C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide
  • 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole
  • CP-320626
  • (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester
  • 8,9,10-trihydroxy-7-hydroxymethyl-3-methyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione
  • Alvocidib
  • 1-deoxy-1-methoxycarbamido-beta-D-glucopyranose
  • N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide
  • 1-Deoxy-1-methoxycarbamido-beta-D-gluco-2-heptulopyranosonamide
  • 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid
  • 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium
  • N(6)-(pyridoxal phosphate)-L-lysine
  • Heptulose-2-Phosphate
  • N-(Benzoylcarbamoyl)-beta-D-glucopyranosylamine
  • Dexfosfoserine
  • 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide
  • Inosinic Acid
  • 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID
  • 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID
  • 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID
  • 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID
  • 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
  • 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
  • (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
  • (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
  • (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL
  • ({[(3E)-2'-Oxo-2',7'-dihydro-2,3'-biindol-3(7H)-ylidene]amino}oxy)acetic acid
  • (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol
  • 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID
  • (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
  • (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
  • Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
RNF10 ring finger protein 10
USHBP1 USH1 protein network component harmonin binding protein 1
ZMIZ2 zinc finger MIZ-type containing 2

Page 1 out of 1 pages